OncoMatch/Clinical Trials/NCT07001709
Determining the Effect of Abiraterone on the Metabolism of Oxycodone in Men With Prostate Cancer (the ENABLE Study)
Is NCT07001709 recruiting? Yes, currently enrolling (Jun 2026). This Phase 4 trial studies multiple treatments including Oxycodone oral capsule 15 mg and Abiraterone Acetate Tablets 500 mg for prostate cancer.
Treatment: Oxycodone oral capsule 15 mg · Abiraterone Acetate Tablets 500 mg — Prostate cancer often leads to bone metastases, which require adequate pain management with opioids such as oxycodone. This study investigates whether abiraterone - a drug used in the treatment of prostate cancer - affects the pharmacokinetics of oxycodone in order to improve pain management.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Prostate Cancer
Biomarker criteria
Excluded: CYP2D6 polymorphism
Excluded: CYP3A4 polymorphism
Demographics
Prior therapy
Cannot have received: chemotherapy
Exception: Subjects who started their first cycle of chemotherapy during the 2 weeks before the study day
Subjects who started their first cycle of chemotherapy during the 2 weeks before the study day
Cannot have received: opioid substitution therapy (methadone, buprenorphine)
Patients receiving opioid substitution therapy for opioid addiction (e.g. methadone or buprenorphine) and/or suffering from opioid withdrawal
Lab requirements
Kidney function
Moderate-severe renal dysfunction (GFR <60 ml/min/1.73m2) that affects drug metabolism [excluded]
Liver function
No active or symptomatic viral hepatitis or chronic liver disease (e.g. classification with Child-Pugh B, Child-Pugh C)
active or symptomatic viral hepatitis or chronic liver disease (e.g. classification with Child-Pugh B, Child-Pugh C); Moderate-severe renal dysfunction (GFR <60 ml/min/1.73m2) that affects drug metabolism
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07001709 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior chemotherapy, opioid substitution therapy disqualifies patients from enrollment.
Are patients with CYP2D6 alterations eligible?
No. CYP2D6 polymorphism is an exclusion criterion.
Are patients with CYP3A4 alterations eligible?
No. CYP3A4 polymorphism is an exclusion criterion.
Is this trial open to female patients?
No. This trial enrolls male patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages